[The HER3/ERBB3 receptor: the dark side of the ERBB planet]

Med Sci (Paris). 2015 May;31(5):465-8. doi: 10.1051/medsci/20153105002. Epub 2015 Jun 9.

[Article in French]

Authors

Christel Larbouret¹, Nadège Gaborit², Marie-Alix Poul¹, André Pèlegrin¹, Thierry Chardès¹

Affiliations

¹ IRCM, institut de recherche en cancérologie de Montpellier, 208, rue des Apothicaires, F-34298, Montpellier, France - Inserm U1194, F-34298, France - Université de Montpellier, Montpellier, F-34090, Montpellier, France - Institut régional du cancer de Montpellier, F-34298, Montpellier, France.
² Department of biological regulation, Weizmann Institute of Science, Rehovot, 76100, Israël.

PMID: 26059291
DOI: 10.1051/medsci/20153105002

No abstract available

Publication types

News
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Screening Assays, Antitumor
ErbB Receptors / genetics
ErbB Receptors / physiology
Humans
Molecular Targeted Therapy
Multigene Family
Mutation
Neoplasm Proteins / antagonists & inhibitors
Neoplasm Proteins / genetics
Neoplasm Proteins / physiology*
Neoplasms / drug therapy
Neoplasms / enzymology
Phosphorylation / drug effects
Protein Kinase Inhibitors / therapeutic use
Protein Processing, Post-Translational / drug effects
Receptor, ErbB-3 / antagonists & inhibitors
Receptor, ErbB-3 / genetics
Receptor, ErbB-3 / physiology*
Signal Transduction / drug effects
Ubiquitination / drug effects

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Neoplasm Proteins
Protein Kinase Inhibitors
ERBB3 protein, human
ErbB Receptors
Receptor, ErbB-3